Anti-HDGF targets cancer and cancer stromal stem cells resistant to chemotherapy

Clinical Cancer Research

Volumn 19, Issue 13, 2013, Pages 3567-3576

  Zhao, Jun ^a,c   Ma, Mark Z ^a   Ren, Hening ^a,b   Liu, Zhenqiu ^b   Edelman, Martin J ^b   Pan, Hong ^a,d   Mao, Li ^a,b  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^d GUANGXI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; GEMCITABINE; HEPATOMA DERIVED GROWTH FACTOR; HISTONE; MONOCLONAL ANTIBODY HDGF H3; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN; HEPATOMA-DERIVED GROWTH FACTOR; MONOCLONAL ANTIBODY; SIGNAL PEPTIDE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CELL PROLIFERATION; CONTROLLED STUDY; DNA EXTRACTION; DOWN REGULATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE SYNTHESIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; STEM CELL GENE THERAPY; STROMA CELL; TREATMENT RESPONSE; TUMOR RECURRENCE; TUMOR VOLUME; UPREGULATION; WEIGHT REDUCTION; WNT SIGNALING PATHWAY; XENOGRAFT; ANIMAL; APOPTOSIS; CANCER GRADING; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION PROFILING; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME;

AGED; ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; RECURRENCE; STROMAL CELLS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879853430     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3478     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jermal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. (Pubitemid 44917502)
3. Reck M, von Pawel J, Zatloukal P, Zatloukal P, Ramlau R, Gorbounova V, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21:1804-9.
4. Everett AD, Stoops T, McNamara CA. Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem 2001;276:37564-8.
5. Nakamura H, Izumoto Y, Kambe H, Kuroda T, Tori T, Kawamura K, et al. Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem 1994;269:25143-9.
6. Lepourcelet M, Tou L, Cai L, Sawada J, Lazar AJ, Glickman JN, et al. Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis ofg ene expression and study of the hepatoma-derived growth factor (HDGF). Development 2005; 132:415-27. (Pubitemid 40268290)
7. Abouzied MM, El-Tahir HM, Prenner L, Haberlein H, Gieselmann V, Franken S. Hepatoma-derived growth factor. Significance of amino acid residues 81-100 in cell surface interaction and proliferative activity. J Biol Chem 2005;280:10945-54. (Pubitemid 40418396)
8. Okuda Y, Nakamura H, Yoshida K, Enomoto H, Uyama H, Hirotani T, et al. Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci 2003;94:1034-41. (Pubitemid 38035516)
9. Everett AD, Narron JV, Stoops T, Nakamura H, Tucker A. Hepatoma derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am J Physiol Lung Cell Mol Physiol 2004;286:L1194-201. (Pubitemid 38656655)
10. Ren H, Tang X, Lee JJ, Feng L, Everett AD, Hong WK, et al. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol 2004;22:3230-7. (Pubitemid 41103677)
11. Zhang J, Ren H, Yuan P, Lang W, Zhang L, Mao L. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res 2006;66:18-23. (Pubitemid 43166002)
12. Ren H, Chu Z, Mao L. Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol Cancer Ther 2009;8:1106-12.
13. Judde JG, Rebucci M, Vogt N, de Gremoux P, Livartowski A, Chapelier A, et al. Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response. Int J Cancer 2007;120:1579-90. (Pubitemid 46355397)
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16. (Pubitemid 30099779)
15. Pathak AK, Bhutani M, Saintigny P, Mao L. Heterotransplant mouse model cohorts of human malignancies: a novel platform for systematic preclinical efficacy evaluation of drugs (SPEED). Am J Transl Res 2009;1:16-22.
16. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012;487:505-9.
17. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Davis A, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487:500-4.
18. Perez-Soler R, Kemp B, Wu QP, Mao L, Gomez J, Zeleniuch-Jacquotte A, et al. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 2000;6:4932-8. (Pubitemid 32110439)
19. John T, Kohler D, Pintilie M, Pham NA, Li M, Panchal D, et al. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clin Cancer Res 2011;17:134-41.
20. Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 2010;5:260-74.
21. Miki T, Yasuda SY, Kahn M. Wnt/b-catenin signaling in embryonic stem cell self-renewal and somatic cell reprogramming. Stem Cell Rev 2011;7:836-46.
22. Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delalove JF, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2011;481:85-9.
23. Shin K, Lee J, Guo N, Kin J, Lim A, Qu L, et al. Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature 2011;472:110-4.
24. Maffini MV, Soto AM, Calabro JM, Ucci AA, Sonnenschein C. The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci 2004;117:1495-502. (Pubitemid 38559824)
25. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335-48. (Pubitemid 40692295)
26. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 2002;32:355-7. (Pubitemid 35266108)
27. Hu M, Yao J, Cai L, Bachman KE, van den Brule F, Velculescu V, et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 2005;37:899-905. (Pubitemid 41077119)
28. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009;138:822-9.
29. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84. (Pubitemid 40488633)
30. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008;26:2839-45.
31. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100:672-9.
32. Driessens G, Beck B, Caauwe A, Simons BD, Blanpain C. Defining the mode of tumour growth by clonal analysis. Nature 2012;488:527-30.
33. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012;488:522-6.
34. Schepers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, van de Wetering M, et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012;337:730-5.
35. Galluzzo P, Bocchetta M. Notch signaling in lung cancer. Expert Rev Anticancer Ther 2011;11:533-40.
36. García Campelo MR, Alonso Curbera G, Aparicio Gallego G, Grande Pulido E, Antón Aparicio LM. Stem cell and lung cancer development: blaming the Wnt, Hh and Notch signalling pathway. Clin Transl Oncol 2011;13:77-83.
37. Liu J, Sato C, Cerletti M, Wagers A. Notch signaling in the regulation of stem cell self-renewal and differentiation. Curr Top Dev Biol 2010;92:367-409.
38. Liu-Jarin X, Stoopler MB, Raftopoulos H, Ginsburg M, Gorenstein L, Borczuk AC. Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy. Mod Pathol 2003;16:1102-8. (Pubitemid 37414204)
39. Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther 2012;11:257-66.
40. Nishimura K, Semba S, Aoyagi K, Sasaki H, Yokozaki H. Mesenchymal stem cells provide an advantageous tumor microenvironment for the restoration of cancer stem cells. Pathobiology 2012;79:290-306.
41. Dieter SM, Ball CR, Hoffmann CM, Nowrouzi A, Herbst F, Zavidij O, et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 2011;9:357-65.